Keros Therapeutics Rings the Opening Bell

ABOUT THIS EVENT

Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, rang the Nasdaq Opening Bell remotely from across the country.

Jasbir S. Seehra, Ph.D., President and CEO, rang the Opening Bell alongside Keros Therapeutics board members, executives, and employees in a virtual bell ringing ceremony.